| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | 1068.22% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 06/07/2022 | 1847.04% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
What is the target price for TransCode Therapeutics (RNAZ)?
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on November 15, 2022. The analyst firm set a price target for $6.00 expecting RNAZ to rise to within 12 months (a possible 1068.22% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a maintained with a price target of $10.00 to $6.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.51, which is out of the analyst's predicted range.